Prostate Cancer: Related News

Memorial Sloan-Kettering urologic surgeon Pramod Sogani has been inaugurated as President of the American Urological Association. In this Q&A he discusses his goals and his new role.

Research suggests that a new drug could be effective in patients with prostate cancer who develop resistance to the targeted therapy enzalutamide.

Dr. Scardino discusses strategies for how physicians and patients can make the best use of PSA testing and prostate cancer treatment.

Dr. Parra, who practices at Memorial Sloan-Kettering Basking Ridge, treats prostate, kidney, and bladder cancers with the goal of extending the lives of patients, and giving them the best possible quality of life.

Dr. Bochner – who specializes in treating people with prostate, bladder, and kidney cancers – discusses the importance of a multidisciplinary team approach to delivering high-quality care.

Researchers at Memorial Sloan-Kettering are developing a new strategy for PET imaging of tumors that could result in new tools to detect and monitor prostate cancer.

Watch urologic surgeon Karim Touijer discuss our comprehensive approach to cancer care and recent advances in minimally invasive surgery.

The American Association for Cancer Research (AACR), the world’s oldest and largest professional organization dedicated to advancing cancer research, held its 2012 annual meeting in Chicago.

Two of the year’s top five cancer research advances cited by the American Society of Clinical Oncology were led by Memorial Sloan-Kettering investigators.

Researchers at Memorial Sloan-Kettering have shown the usefulness of a scale called the Bone Scan Index (BSI) for determining whether some prostate cancer patients are responding to therapy.

Memorial Sloan-Kettering researchers have discovered that the AR and PI3K disease pathways regulate each other through reciprocal negative feedback.

The drug finasteride, used to treat benign enlargement of the prostate, has been shown in a large, randomized study to prevent prostate cancer, reducing the risk of the disease by close to 25 percent. However, the drug is not widely used as a preventive, which experts attribute to the modest benefit it offers to the average man. In a recent analysis of the data from the original study, investigators from Memorial Sloan-Kettering Cancer Center have found that finasteride is best given only to men at higher than average risk of getting prostate cancer.

A prostate-specific antigen (PSA) test taken for the first time between the ages of 44 and 50 can predict the likelihood that a man will die from prostate cancer over the next 25 to 30 years, according to researchers at Memorial Sloan-Kettering Cancer Center.

A blood test at the age of 60 can accurately predict the risk that a man will die from prostate cancer within the next 25 years, according to researchers at Memorial Sloan-Kettering Cancer Center, in New York, and Lund University, in Sweden. The findings were published today online in the British Medical Journal.

An experimental drug is showing promise for the treatment of men with an aggressive form of advanced prostate cancer. A new multicenter study has concluded that the targeted therapy MDV3100 is safe and effective for patients with castration-resistant prostate cancer, known for its poor prognosis and limited treatment options.

Investigators at Memorial Sloan-Kettering Cancer Center, along with collaborating teams at the Cleveland Clinic and the University of Michigan, have completed the first large-scale, multi-institutional study of prostate cancer death after standard treatment to remove the prostate since PSA screening has become widely used as a method to screen for the disease.

A single prostate specific antigen (PSA) test taken before the age of 50 can be used to predict advanced prostate cancer in men up to 25 years in advance of a diagnosis, according to a new study published by researchers at Memorial Sloan-Kettering Cancer Center in New York and Lund University in Sweden.